Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 18)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for PIP 13 $25 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala PHARMATHENE INC (PIP=US) 12-months forecast 1 $15 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Biotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards. 63 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A Pepsi-Cola Products Philippines Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A Pipe Works L.Tzirakian-Profil SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A PharmAthene Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Pechala's Reports Lubomir Pechala PHARMATHENE INC (PIP=US) 2-weeks forecast 1 $10 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: PHARMATHENE -- PIP 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ARYX , DSCO , HEPH , ICGN , MSHL , OGXI , PIP , SOMX -- DRUGS 3 $4 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for PIP: the economy's impact on PIP's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
Next 8

Independent Reports (Showing 1 to 10 of 18)

Release
Date Contributor Author Title Pages Price More Info
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for PIP 13 $25 View Abstract
7-Feb-10 Pechala's Reports Frantisek Pechala PHARMATHENE INC (PIP=US) 12-months forecast 1 $15 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Biotechnology Intelligence Monitor: overall outlook NEUTRAL - 23 new Leaders; 25 new Laggards. 63 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A Pepsi-Cola Products Philippines Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A Pipe Works L.Tzirakian-Profil SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A PharmAthene Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Pechala's Reports Lubomir Pechala PHARMATHENE INC (PIP=US) 2-weeks forecast 1 $10 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: PHARMATHENE -- PIP 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ARYX , DSCO , HEPH , ICGN , MSHL , OGXI , PIP , SOMX -- DRUGS 3 $4 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for PIP: the economy's impact on PIP's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
Next 8

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.